Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

A Phase 3, randomized, 2-arm, open-label, multicenter, stratified study of soquelitinib versus physician's choice standard of care (SOC) treatment (selected single agents) in participants with relapsed/refractory (R/R) peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), follicular helper T-cell lymphomas (FHTCLs), or systemic anaplastic large-cell lymphoma (sALCL).

Trial Details

NCT ID
NCT06561048
Phase
PHASE3
Sponsor
Corvus Pharmaceuticals, Inc.
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Soquelitinib
  • Belinostat
  • Pralatrexate
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Irvine, California, United States|33.66946,-117.82311
  • San Francisco, California, United States|37.77493,-122.41942
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • Miami, Florida, United States|25.77427,-80.19366

Key Eligibility Criteria

  • Adult participants ≥18 years of age on the day of signing the informed consent form.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2.
  • Histologically confirmed PTCL-NOS, FHTCLs or sALCL per The International Consensus Classification of Mature Lymphoid Neoplasms.
  • Progressed on, be refractory to, relapsed, or intolerant to standard therapy for their cancer. At least 1 but not more than 3 prior systemic therap…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →